Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02935309 · ClinicalTrials.gov registry record · Phase 1
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02935309 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 20 participants.
The verdict
NCT02935309, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This research study is designed to see if Capecitabine and Lenvatinib in combination with external radiation therapy are effective in treating locally advanced rectal adenocarcinoma in patients who have not yet had surgery, and what the best dosage is.
Interventions
- DRUG Capecitabine
- DRUG Lenvatinib
- RADIATION External Radiation Therapy (XRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-10-14 |
| Est. Completion | 2020-05-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02935309
The ClinicalTrials.gov registry entry for NCT02935309 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT02935309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02935309 about?
NCT02935309 is a clinical study titled "Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma". This research study is designed to see if Capecitabine and Lenvatinib in combination with external radiation therapy are effective in treating locally advanced rectal adenocarcinoma in patients who have not yet had surgery, and what the best dosage is.
What is the current status of trial NCT02935309?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-10-14. Estimated completion is 2020-05-14.
What interventions are being tested in trial NCT02935309?
The interventions under investigation include: Capecitabine (DRUG), Lenvatinib (DRUG), External Radiation Therapy (XRT) (RADIATION).
Who is sponsoring clinical trial NCT02935309?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.